Technology · 1 views
Moving faster than planned, AI drug developer Accipiter Bio quietly tops up seed round with $10.5M
Seattle biotech startup Accipiter Bio has raised an additional $10.5 million from existing investors to accelerate its work on AI-designe…
AI Summary
Seattle biotech startup Accipiter Bio has raised an additional $10.5 million from existing investors to accelerate its work on AI-designed, multi-target protein therapeutics. Fueled by faster-than-expected progress, the company plans to use the new capital to expand its team and double its roster of clinical-stage drug candidates, with a growing focus on im…
Read full article on GeekwireAI summaries can be wrong sometimes—always verify important details using the source article.
Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.
Support HappeningNowMore from Technology
Continue reading recent Technology coverage